{"id":399716,"date":"2020-12-15T07:58:07","date_gmt":"2020-12-15T12:58:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399716"},"modified":"2020-12-15T07:58:07","modified_gmt":"2020-12-15T12:58:07","slug":"karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/","title":{"rendered":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy"},"content":{"rendered":"<div class=\"mw_release\">\n<p>RALEIGH, N.C., Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer\u2019s patients.<\/p>\n<p>The grant builds on Karamedica\u2019s nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA. Karamedica\u2019s CAA therapy consists of \u201csmart\u201d microparticles made from chitosan, which is derived from chitin, a biopolymer obtained commercially from crustacean shells.<\/p>\n<p>\u201cWe made great strides in the Phase I with support of NIH and our collaborators,\u201d said Wolff Kirsch, MD, Karamedica Chairman &amp; CEO. \u201cIn Phase II, we will expand the scientific and clinical team and begin an in-depth analysis of this promising therapy in an animal model.\u201d<\/p>\n<p>The project\u2019s aims include optimizing synthesis of chitosan microparticles and characterizing effects of optimized microparticles in a preclinical mouse study. Specifically, the research team is assessing the biodistribution, pharmacokinetics and pharmacodynamics of intranasally administered microparticles containing a genetic construct that may slow or prevent cognitive decline from CAA. Karamedica\u2019s scientists and their collaborators are also assessing blood brain barrier integrity and cognitive function of mice before and after treatment to quantify benefits of the chitosan microparticle therapy. Karamedica\u2019s chitosan microparticles may prevent injuries to the cells of the brain\u2019s blood vessels by triggering them to increase production of CD59, a natural inhibitor of a molecule formed by the immune system called the complement membrane attack complex.<\/p>\n<p>Karamedica is building on its partnership with scientists at Loma Linda University, North Carolina State University, UCLA, UC Riverside, and Walla Walla University<\/p>\n<p>\u201cWe are excited to continue working with our world-renowned collaborators toward translating this novel therapy to clinical use,\u201d said company President Andrew Crofton, PhD. \u201cWe truly believe this therapy will revolutionize treatment of this terrible disease while also enabling therapies for other neurological disorders.\u201d<\/p>\n<p>ABOUT KARAMEDICA<br \/>Karamedica\u2019s goal is to expand medical and veterinary uses of biopolymer-based products, especially those containing chitosan, by developing novel decontamination processes like non-thermal plasmas. Karamedica also creates innovative medical devices and drug delivery systems based on these biopolymers.<\/p>\n<p>CONTACT<br \/>Taub T Swartz<br \/>CFO<br \/>taub.swartz@karamedica.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/758cc9cd-072f-47a1-a4ce-70cf6b3758f3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RALEIGH, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer\u2019s patients. The grant builds on Karamedica\u2019s nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA. Karamedica\u2019s CAA therapy consists of \u201csmart\u201d microparticles made from chitosan, which is derived from chitin, a biopolymer obtained commercially from crustacean shells. \u201cWe made great strides in the Phase I with support of NIH and our collaborators,\u201d said Wolff Kirsch, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399716","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RALEIGH, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer\u2019s patients. The grant builds on Karamedica\u2019s nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA. Karamedica\u2019s CAA therapy consists of \u201csmart\u201d microparticles made from chitosan, which is derived from chitin, a biopolymer obtained commercially from crustacean shells. \u201cWe made great strides in the Phase I with support of NIH and our collaborators,\u201d said Wolff Kirsch, &hellip; Continue reading &quot;Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T12:58:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy\",\"datePublished\":\"2020-12-15T12:58:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/\"},\"wordCount\":399,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/\",\"name\":\"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\",\"datePublished\":\"2020-12-15T12:58:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/","og_locale":"en_US","og_type":"article","og_title":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk","og_description":"RALEIGH, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to continue developing a microparticle therapy for treating cerebral amyloid angiopathy (CAA), a condition responsible for inflicting significant neurologic damage and afflicting greater than 85% of Alzheimer\u2019s patients. The grant builds on Karamedica\u2019s nose-to-brain delivery system that was validated in the Phase I SBIR proof-of-concept studies using mouse models of CAA. Karamedica\u2019s CAA therapy consists of \u201csmart\u201d microparticles made from chitosan, which is derived from chitin, a biopolymer obtained commercially from crustacean shells. \u201cWe made great strides in the Phase I with support of NIH and our collaborators,\u201d said Wolff Kirsch, &hellip; Continue reading \"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T12:58:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy","datePublished":"2020-12-15T12:58:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/"},"wordCount":399,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/","name":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=","datePublished":"2020-12-15T12:58:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMTI4MyMzODY4MzMzIzIxMjQ0NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/karamedica-announces-national-institute-on-aging-grant-to-continue-development-of-microparticle-therapy-for-cerebral-amyloid-angiopathy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399716"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399716\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}